

Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression

Sep 22, 2010

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/novartis-gains-fda-approval-gilenyatm-novel-first-line-multiple-sclerosis-treatment-shown-significantly-reduce-relapses-and-delay-disability-progression-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-gains-fda-approval-gilenyatm-novel-first-line-multiple-sclerosis-treatment-shown-significantly-reduce-relapses-and-delay-disability-progression-0>